About Bio Rad Laboratories Inc
- Industry: Life Sciences Tools & Services
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.bio-rad.com/
Frequently Asked Questions
What is the 52-week range for BIO?
The 52-week high is $396.23 and the 52-week low is $236.73.
What is the P/E ratio for BIO?
The Price to Earnings (P/E) ratio is 44.42.
What is the dividend yield for BIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 3.15%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 8.59%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.10.
Analyst Recommendation Trends
Wall Street analyst consensus for BIO over the last few months:
Latest BIO News
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
Biologics, biosimilars and personalized therapies are fueling CDMO outsourcing, while AI, automation and single-use systems enable scalable, compliant protein production.Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030 The global recombinant proteins manufacturing services m
Why Bio Rad Laboratories (BIO) Is Back In The Spotlight
Bio-Rad Laboratories (BIO) has drawn attention after recent share performance data showed a decline of about 2% over the past month, alongside a gain of roughly 27% over the past three months. At a share price of US$377.71, Bio-Rad Laboratories has seen short term share price momentum cool over the past month. However, the 90 day share price return of about 27% and 1 year total shareholder return of roughly 27% suggest sentiment has improved compared with the much weaker 5 year total...
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Magnetic Beads - Global Strategic Business Report: Capitalize on the Surge from $3.3 Billion in 2025 to $7.4 Billion by 2032 as Thermo Fisher Scientific, Merck KGaA, QIAGEN, Bio-Rad Laboratories and Miltenyi Biotec Battle for Leadership
Demand is rising in diagnostics, precision medicine and biopharma research, while nanotechnology, automation and AI unlock targeted therapies and high-throughput workflows.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Magnetic Beads - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global magnetic beads market was valued at an estimated US$3.3 billion in 2025 and is projected to reach US$7.4 billion by 2032, advancing at a compound annual growth rate (CAG
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories (NYSE:BIO) is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective approach to acquisitions. Speaking at a Bernstein conference, Chief Financial Offic
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 24, 2026 8:50 AM EDTCompany...
Cell Isolation/Cell Separation Market Forecasts Growth from $6.97B (2026) to $13.51B by 2032, Profiling Thermo Fisher, Bio-Rad, Beckman Coulter & Sartorius
Opportunities include automated closed systems, AI-enabled quality control, single-cell and cell therapy workflows, precision medicine, advanced diagnostics and emerging-market expansion.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Cell Isolation/Cell Separation Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The market research report examines the global Cell Isolation/Cell Separation Market, which is projected to reach USD 6.97 billion in 2026 and grow a
Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher
Biodesix, Inc. (NASDAQ:BDSX) reported progress in two collaborative Molecular Residual Disease (MRD) monitoring programs designed to detect circulating tumor DNA (ctDNA) in blood following cancer treatment.
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertiseLOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions intended to support cancer centers and clinical laboratories. Both solutions detect circulating tum
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Capitalize on the Therapeutic Drug Monitoring Shift: Benchmark Roche, Abbott, Siemens Healthineers, Thermo Fisher and Bio-Rad to Accelerate Revenue and Defend Market Share
Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Therapeutic Drug Monitoring was estimated at US$1.5 Billion in 2025 and is projected to reach US$2.6 Billion by 2032, growing at a CAGR of 8
Capitalize on Label-Free Array Systems Disruption: Benchmark Agilent, Cytiva, Sartorius, Bio-Rad and PerkinElmer to Secure R&D ROI and Global Market Share
Demand is rising for real-time biomolecular analysis in drug discovery and diagnostics, driven by SPR/BLI advances, automation, high-throughput screening and biomarker research.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-free Array Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-free Array Systems was valued at US$1.8 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 5.6% from 2
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif., September 16, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time.
Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues
Bio-Rad Laboratories has delivered a sharp mix of outcomes for long term holders, with the stock down about 52.9% over 5 years even as shorter term returns have turned positive. This puts the spotlight on what its current share price implies about the cash the business can generate. With the valuation lens focused on cash flows through a Discounted Cash Flow (DCF) framework, the question is how well today's market price lines up with the stream of money the company may produce for...
Transcriptome Sequencing Market - Global Forecast to 2035; Bulk RNA-Seq Maintains Its Technology Market Lead
The global transcriptome sequencing market is projected to reach $11.8 billion by 2035, growing at a 7.3% CAGR from 2025 to 2035. Growth is driven by falling sequencing costs, precision medicine, drug discovery, biomarker development, single-cell and spatial transcriptomics, long-read RNA sequencing, and AI-powered analytics. Consumables, bulk RNA-seq, drug discovery applications, and pharmaceutical and biotechnology companies led the market in 2025. North America held the largest regional share
Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 3:45 PM EDTCompany ParticipantsRoop Lakkaraju - Executive...
ILMN Stock Keeps Climbing. Should You Climb On?
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with a 34% share, while Asia Pacific is the fastest-growing region at 15.5%; India is forecast to expand at 16.9%. Consumables account for 68% of sales and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, biomarker R&D, molecular diagnostics and laboratory automation. Key players include Thermo Fisher
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-05-11 | ENGELHARDT EVA ANETTE | -550 | $246.54 | $135,597 |
| 2026-04-24 | ENLOE COURTNEY C | -186 | - | - |
| 2026-04-24 | ENLOE COURTNEY C | -77 | $287.84 | $22,164 |
| 2026-04-24 | ENLOE COURTNEY C | +186 | - | - |
| 2026-04-24 | Lakkaraju Roop Kalyan | -1,078 | - | - |
| 2026-04-24 | Lakkaraju Roop Kalyan | -420 | $287.84 | $120,893 |
| 2026-04-24 | Lakkaraju Roop Kalyan | +1,078 | - | - |
| 2026-04-21 | PEI MELINDA LITHERLAND | -407 | - | - |
| 2026-04-21 | PEI MELINDA LITHERLAND | +369 | - | - |
| 2026-04-21 | PEI MELINDA LITHERLAND | +407 | - | - |
| 2026-04-21 | PINKSTON ARNOLD A | -407 | - | - |
| 2026-04-21 | PINKSTON ARNOLD A | +369 | - | - |
| 2026-04-21 | PINKSTON ARNOLD A | +407 | - | - |
| 2026-04-21 | Hinckley Greg K | -407 | - | - |
| 2026-04-21 | Hinckley Greg K | +369 | - | - |
| 2026-04-21 | Hinckley Greg K | +407 | - | - |
| 2026-04-21 | EDWARDS JEFFREY L | -407 | - | - |
| 2026-04-21 | EDWARDS JEFFREY L | +369 | - | - |
| 2026-04-21 | EDWARDS JEFFREY L | +407 | - | - |
| 2025-11-06 | BARRY JAMES | -700 | $306.182 | $214,327 |
| 2025-10-24 | DiVincenzo Jonathan P. | -1,869 | - | - |
| 2025-10-24 | DiVincenzo Jonathan P. | -950 | $339.75 | $322,763 |
| 2025-10-24 | DiVincenzo Jonathan P. | +1,869 | - | - |
| 2025-10-20 | EVRAN SEDAT | -1,044 | - | - |
| 2025-10-20 | EVRAN SEDAT | -335 | $321.9 | $107,836 |
| 2025-10-20 | EVRAN SEDAT | +1,044 | - | - |